Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells

STAT3 inhibition as a therapeutic strategy for leukemia

(2017) Rubashruti Kanna et al.   LEUKEMIA & LYMPHOMA

FDA-Approved Oligonucleotide Therapies in 2017

(2017) Cy A. Stein et al.   MOLECULAR THERAPY

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Antisense oligonucleotides: the next frontier for treatment of neurological disorders

(2017) Carlo Rinaldi et al.   Nature Reviews Neurology

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy

(2017) Richard S. Finkel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

(2017) Sarah J. Ross et al.   Science Translational Medicine

Inhibition of STAT3 with the Generation 2.5 Antisense Oligonucleotide, AZD9150, Decreases Neuroblastoma Tumorigenicity and Increases Chemosensitivity

(2016) Seiichi Odate et al.   CLINICAL CANCER RESEARCH

Musashi-2 promotes migration and invasion in bladder cancer via activation of the JAK2/STAT3 pathway

(2016) Chenlu Yang et al.   LABORATORY INVESTIGATION

A 17-gene stemness score for rapid determination of risk in acute leukaemia

(2016) Stanley W. K. Ng et al.   NATURE

Treatment of low-risk myelodysplastic syndromes

(2016) V. Santini   Hematology-American Society of Hematology Education Program

IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells

(2015) C. Schinke et al.   BLOOD

Small molecule Mcl-1 inhibitors for the treatment of cancer

(2015) Johannes Belmar et al.   PHARMACOLOGY & THERAPEUTICS

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

(2015) David Hong et al.   Science Translational Medicine

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes

(2015) Moritz Gerstung et al.   Nature Communications

Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner

(2015) Shankar Varadarajan et al.   Oncotarget

Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo

(2014) Petter S. Woll et al.   CANCER CELL

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

(2014) Liran I. Shlush et al.   NATURE

Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes

(2013) W. W. Pang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia

(2012) A. Jerez et al.   BLOOD

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS

(2012) L. Barreyro et al.   BLOOD

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations

(2012) B. Will et al.   BLOOD

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

(2012) S. P. Glaser et al.   GENES & DEVELOPMENT

Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia

(2012) M. Jan et al.   Science Translational Medicine

STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma

(2011) A. Scuto et al.   CANCER RESEARCH

Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways

(2011) Ayumi Takakura et al.   HUMAN MOLECULAR GENETICS

Antisense Oligonucleotides Containing Conformationally Constrained 2′,4′-(N-Methoxy)aminomethylene and 2′,4′-Aminooxymethylene and 2′-O,4′-C-Aminomethylene Bridged Nucleoside Analogues Show Improved Potency in Animal Models

(2010) Thazha P. Prakash et al.   JOURNAL OF MEDICINAL CHEMISTRY

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells

(2010) A Pellagatti et al.   LEUKEMIA

Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia

(2010) Michael G Kharas et al.   NATURE MEDICINE

Short Antisense Oligonucleotides with Novel 2′−4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals

(2008) Punit P. Seth et al.   JOURNAL OF MEDICINAL CHEMISTRY

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome

(2008) Benjamin L Ebert et al.   PLOS MEDICINE